OKYO (OKYO Pharma) EBIT per Share: $-0.15 (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OKYO OKYO Pharma Ltd OKYO
23 GF Score
Price $1.41
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma EBIT per Share?

OKYO Pharma OKYO +1.81% 23 EBIT per Share is $-0.15 as of Sep. 2025. GuruFocus rates OKYO with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,173 Biotechnology companies, OKYO Pharma ranks worse than 99.57% on this metric.

OKYO Pharma's EBIT per Share for the six months ended in Sep. 2025 was $-0.07. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.15.

During the past 3 years, the average EBIT per Share Growth Rate was -182.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -111.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was -77.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for OKYO Pharma's EBIT per Share or its related term are showing as below:

OKYO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -482.2   Med: -18.2   Max: 84.6
Current: -182.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of OKYO Pharma was 84.60% per year. The lowest was -482.20% per year. And the median was -18.20% per year.

OKYO's 3-Year EBIT Growth Rate is ranked worse than
99.57% of 1173 companies
in the Biotechnology industry
Industry Median: 15.5 vs OKYO: -182.30

OKYO Pharma's EBIT for the six months ended in Sep. 2025 was $-2.50 Mil.

OKYO Pharma  (NAS:OKYO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

OKYO Pharma EBIT per Share Related Terms

OKYO Pharma EBIT per Share Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma EBIT per Share Chart

OKYO Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.33 -0.01 -0.59 -0.54 -0.18

OKYO Pharma Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.21 -0.10 -0.08 -0.07
OKYO
23GF Score
OKYO Pharma Ltd OKYO
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

OKYO Pharma's EBIT per Share for the fiscal year that ended in Mar. 2025 is calculated as

EBIT per Share(A: Mar. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-7.1/39.488
=-0.18

OKYO Pharma's EBIT per Share for the quarter that ended in Sep. 2025 is calculated as

EBIT per Share(Q: Sep. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.502/37.421
=-0.07

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.15 mean?
OKYO Pharma (OKYO) has a EBIT per Share of $-0.15 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on OKYO Pharma and its competitors. According to the industry distribution chart, OKYO Pharma ranks #1168 out of 1173 companies in the Biotechnology industry, placing it in the top 99.6%.
Is OKYO Pharma's EBIT per Share too high?
OKYO Pharma's current EBIT per Share is $-0.15. Based on the distribution chart, OKYO Pharma ranks #1168 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's EBIT per Share compare to ENTX and HRTX?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #1168 out of 1173 companies for EBIT per Share. This places OKYO Pharma in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on OKYO Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OKYO Pharma's current EBIT per Share is $-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (OKYO) has a current EBIT per Share of $-0.15. The current EBIT per Share is $-0.15. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For OKYO Pharma (OKYO), the current EBIT per Share is $-0.15 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for OKYO

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.41
Price